Danaher's $9.9B Masimo Deal Marks One of 2026's Largest Medtech Buyouts
Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share.
Danaher to acquire Masimo in $9.9B all-cash deal
Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) in an all-cash transaction valued at approximately $9.9 billion, as the life sciences and diagnostics company looks to expand its patient monitoring capabilities. Under the terms of the agreement, Danaher will acquire all outstanding Masimo common shares for $180 per share in cash.
Danaher closes in on nearly $10 billion deal for Masimo, FT reports
US healthcare manufacturer Danaher is closing in a nearly $10 billion deal to acquire medical technology company Masimo , the Financial Times reported on Monday, citing people familiar with the matter.
Danaher Stock Plunge Does Not Represent A Good Entry Point
Danaher Stock Plunge Does Not Represent A Good Entry Point
Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR beats Q4 estimates as sales rise 4.5%, driven by strength across Life Sciences, Diagnostics and Biotech, and issued upbeat 2026 earnings guidance.
Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript
Danaher Corporation (DHR) Q4 2025 Earnings Call Transcript
Compared to Estimates, Danaher (DHR) Q4 Earnings: A Look at Key Metrics
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Beats Q4 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.14 per share a year ago.
Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
Life sciences firm Danaher Corp forecast annual profit largely in line with Wall Street estimates on Wednesday and beat fourth-quarter profit and revenue expectations, as improving conditions in the pharmaceutical market and reduced policy uncertainties offset weakness in academic research funding.
Insights Into Danaher (DHR) Q4: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Danaher (DHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
DHR is set to report Q4 results on Jan. 28, with revenues seen up 3.9% and bioprocessing and diagnostics strength in focus.
Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
